| FORMYCON AG |
| Deutschland |
| Gesundheit |
| DE000A1EWVY8 / A1EWVY |
| FYB (Frankfurt) |
| FRA:FYB, ETR:FYB, FYB:GR |
| - |
| https://www.formycon.com/ |
|
Formycon AG is a leading independent biotechnology company headquartered in Planegg, Germany, specializing in the development of high-quality biosimilars, which are cost-effective follow-on versions of complex biopharmaceutical medicines. The company..
>Volltext.. |
| 340.89 Mio. EUR |
| 297.6 Mio. EUR |
| 60.36 Mio. EUR |
| 10.06 Mio. EUR |
| -24.77 Mio. EUR |
| -1.4 EUR |
| 8.39 Mio. EUR |
| 51.04 Mio. EUR |
| -4.81 Mio. EUR |
| 0.96 |
| 18.28% |
| 85.2% |
| - |
| - |
| - |
| - |
| FORMYCON, NANOHALE |
| 07.09.26 |
|